{"id":{"repo_id":"msu","oai_identifier":"oai:d.lib.msu.edu:etd_53275"},"canonical_url":"https://search.ndltd.org/etd/msu/oai:d.lib.msu.edu:etd_53275","repository":{"repo_id":"msu","name":"Michigan State University","base_url":"https://d.lib.msu.edu/oai"},"display":{"title":"IMMUNE EVASION IN HUMAN PAPILLOMAVIRUS-POSITIVE HEAD AND NECK CANCER BY MHC-I DEGRADATION","abstract":"Thesis (Ph.D.)--Michigan State University. Cell and Molecular Biology - Doctor of Philosophy, 2026","abstract_html":"Thesis (Ph.D.)--Michigan State University. Cell and Molecular Biology - Doctor of Philosophy, 2026","abstract_has_math":false,"creators":["Vu, Lexi Thanh-Truc"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Pyeon, Dohun","Olive, Andrew J","Gallo, Kathleen A","MacKeigan, Jeffrey P","Park, Sangbum"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-18T18:59:44Z","subjects":["Molecular biology","Immunology","Virology"],"languages":["eng"],"rights":["In Copyright"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:53275","local:Vu_grad.msu_0128D_22323"],"render_values":[{"text":"etd:53275","href":null,"code":true},{"text":"local:Vu_grad.msu_0128D_22323","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://doi.org/doi:10.25335/5xgx-4w57","outbound_label":"DOI","outbound_source":"dc:identifier","record_url":"https://doi.org/doi:10.25335/5xgx-4w57","record_label":"Repository record","record_kind":"doi","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://d.lib.msu.edu/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Ad.lib.msu.edu%3Aetd_53275","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Pyeon, Dohun","Olive, Andrew J","Gallo, Kathleen A","MacKeigan, Jeffrey P","Park, Sangbum"]},{"key":"dc:creator","label":"Author","values":["Vu, Lexi Thanh-Truc"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2026"]},{"key":"dc:relation","label":"Dc Relation","values":["Electronic Theses & Dissertations"]},{"key":"dc:type","label":"Dc Type","values":["text","Electronic dissertations"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Molecular biology","Immunology","Virology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["In Copyright"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:53275","local:Vu_grad.msu_0128D_22323","https://doi.org/doi:10.25335/5xgx-4w57"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Thesis (Ph.D.)--Michigan State University. Cell and Molecular Biology - Doctor of Philosophy, 2026","Human papillomaviruses (HPVs) are the causative agent of ~5% of all human cancers, including >99% of cervical cancers and ~25% of head and neck cancers (HNCs). Standard treatments include chemotherapy, radiation, and surgery. While effective, these treatments are often accompanied by side effects that significantly decrease the patients’ quality of life. Thus, there is an urgent need to develop safe, yet effective therapeutic alternatives for the treatment of HPV+ HNC. HPV-driven cancer progression requires persistent infection with high-risk HPV genotypes and evasion of the host immune response. Accordingly, HPV has evolved strategies to evade immune surveillance, including the downregulation of major histocompatibility complex class I (MHC-I) on the cell surface. MHC-I downregulation impairs CD8+ T-cell recognition of tumor cells, thereby enabling cancer cell persistence. Consistent with this, diminished MHC-I cell surface expression has been linked to poor responses to immune checkpoint inhibitors (ICIs). Therefore, identifying mechanisms of MHC-I downregulation is critical for enhancing the efficacy of current treatment strategies. This thesis focuses on uncovering how MHC-I protein is degraded in HPV+ HNC and identifying strategies to restore MHC-I expression on the cell surface to enhance antitumor immunity. Here, we demonstrate that MHC-I is ubiquitinated by the E3 ubiquitin ligase MARCHF8, recognized by the selective autophagy receptor NDP52, and degraded via selective autophagy. Through genome-wide CRISPR screens and validation using single gene knockouts, we show that inhibiting the initiation and nucleation steps of autophagy, the ULK1 and Beclin1 autophagy initiation complexes, is critical for restoring MHC-I on the cell surface. Genetic knockout of ULK1 in our HPV+ HNC mouse model resulted in significant tumor suppression and an enhanced CD8+ T-cell antitumor response. To restore surface MHC-I, we propose using alisertib, a small-molecule inhibitor that disrupts the interaction between MYC, the driver of MARCHF8 expression, and its stabilizer, AURKA. We demonstrate that treatment of HPV+ HNC cells with alisertib suppresses MARCHF8 promoter activity and reduces mRNA and protein levels, thereby increasing MHC-I cell-surface expression.","Description based on online resource. Title from PDF t.p. (Michigan State University Fedora Repository, viewed ).","Includes bibliographical references."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf","1 online resource (136 p.) : ill."]},{"key":"dc:title","label":"Title","values":["IMMUNE EVASION IN HUMAN PAPILLOMAVIRUS-POSITIVE HEAD AND NECK CANCER BY MHC-I DEGRADATION"]}]}],"canonical_facts":{"dc:contributor":["Pyeon, Dohun","Olive, Andrew J","Gallo, Kathleen A","MacKeigan, Jeffrey P","Park, Sangbum"],"dc:creator":["Vu, Lexi Thanh-Truc"],"dc:date":["2026"],"dc:description":["Thesis (Ph.D.)--Michigan State University. Cell and Molecular Biology - Doctor of Philosophy, 2026","Human papillomaviruses (HPVs) are the causative agent of ~5% of all human cancers, including >99% of cervical cancers and ~25% of head and neck cancers (HNCs). Standard treatments include chemotherapy, radiation, and surgery. While effective, these treatments are often accompanied by side effects that significantly decrease the patients’ quality of life. Thus, there is an urgent need to develop safe, yet effective therapeutic alternatives for the treatment of HPV+ HNC. HPV-driven cancer progression requires persistent infection with high-risk HPV genotypes and evasion of the host immune response. Accordingly, HPV has evolved strategies to evade immune surveillance, including the downregulation of major histocompatibility complex class I (MHC-I) on the cell surface. MHC-I downregulation impairs CD8+ T-cell recognition of tumor cells, thereby enabling cancer cell persistence. Consistent with this, diminished MHC-I cell surface expression has been linked to poor responses to immune checkpoint inhibitors (ICIs). Therefore, identifying mechanisms of MHC-I downregulation is critical for enhancing the efficacy of current treatment strategies. This thesis focuses on uncovering how MHC-I protein is degraded in HPV+ HNC and identifying strategies to restore MHC-I expression on the cell surface to enhance antitumor immunity. Here, we demonstrate that MHC-I is ubiquitinated by the E3 ubiquitin ligase MARCHF8, recognized by the selective autophagy receptor NDP52, and degraded via selective autophagy. Through genome-wide CRISPR screens and validation using single gene knockouts, we show that inhibiting the initiation and nucleation steps of autophagy, the ULK1 and Beclin1 autophagy initiation complexes, is critical for restoring MHC-I on the cell surface. Genetic knockout of ULK1 in our HPV+ HNC mouse model resulted in significant tumor suppression and an enhanced CD8+ T-cell antitumor response. To restore surface MHC-I, we propose using alisertib, a small-molecule inhibitor that disrupts the interaction between MYC, the driver of MARCHF8 expression, and its stabilizer, AURKA. We demonstrate that treatment of HPV+ HNC cells with alisertib suppresses MARCHF8 promoter activity and reduces mRNA and protein levels, thereby increasing MHC-I cell-surface expression.","Description based on online resource. Title from PDF t.p. (Michigan State University Fedora Repository, viewed ).","Includes bibliographical references."],"dc:format":["application/pdf","1 online resource (136 p.) : ill."],"dc:identifier":["etd:53275","local:Vu_grad.msu_0128D_22323","https://doi.org/doi:10.25335/5xgx-4w57"],"dc:language":["eng"],"dc:relation":["Electronic Theses & Dissertations"],"dc:rights":["In Copyright"],"dc:subject":["Molecular biology","Immunology","Virology"],"dc:title":["IMMUNE EVASION IN HUMAN PAPILLOMAVIRUS-POSITIVE HEAD AND NECK CANCER BY MHC-I DEGRADATION"],"dc:type":["text","Electronic dissertations"]},"updated_at":"2026-11-18T18:59:44Z"}